XML 48 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Debt - Additional Information (Detail)
$ in Thousands
1 Months Ended 3 Months Ended 5 Months Ended 6 Months Ended
May 09, 2023
USD ($)
Apr. 06, 2022
USD ($)
Jul. 06, 2021
USD ($)
Aug. 13, 2020
USD ($)
Installment
Oct. 31, 2021
PrivatePlacement
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Oct. 31, 2021
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Total payoff amount of term loan                   $ 9,409
Interest expense           $ 1 $ 153   $ 2 $ 384
Private Placement [Member]                    
Number of private placements | PrivatePlacement         2          
SVB Term Loan [Member]                    
Total payoff amount of term loan $ 6,500                  
Term loan 5,200                  
Debt instrument, principal amount 0     $ 14,000            
Interest-only payment period       24 months            
Loan payment, number of consecutive equal monthly installments of principal including accrued interest | Installment       24            
Debt instrument, maturity date                 Feb. 01, 2024  
Debt instrument, final payment fee amount 1,200     $ 1,200            
Debt default additional interest charge       5.00%            
Interest rate, floating             9.45%     10.25%
Interest expense           $ 0 $ 151   $ 0 $ 382
Debt instrument accrued interest and prepayment premium $ 100                  
SVB Term Loan [Member] | Minimum [Member]                    
Interest rate, floating       4.25%            
Long term debt percentage bearing adjusted floating interest rate       6.25%            
SVB Term Loan [Member] | First Amendment                    
Debt instruments percentage of required to deposit unrestricted and unencumbered cash collateral     100.00%              
Equity raise requirements, description                 if the Company failed to receive positive data in its Phase 2b/3 PRISM trial or to raise by June 30, 2022 sufficient net proceeds from the sale of equity securities to finance its planned second Phase 3 clinical trial of Haduvio for prurigo nodularis and its ongoing operations (each a “Milestone Condition”), the Company would have been required to deposit unrestricted and unencumbered cash equal to 100% of all outstanding amounts owed to SVB in a cash collateral account with SVB, which could have been used by SVB to prepay the SVB Term Loan at any time.  
SVB Term Loan [Member] | First Amendment | Minimum [Member]                    
Debt instruments amount of required to maintain unrestricted and unencumbered cash     $ 20,000              
Proceeds from the sale of equity securities               $ 15,000    
SVB Term Loan [Member] | Third Amendment [Member]                    
Variable interest rate   3.00%                
Proceeds from the sale of equity securities   $ 45,000                
SVB Term Loan [Member] | Third Amendment [Member] | Minimum [Member]                    
Interest rate, floating   4.25%                
Long term debt percentage bearing adjusted floating interest rate   6.25%                
SVB Term Loan [Member] | Prepayment Prior to First Anniversary of Effective Date [Member]                    
Prepayment premium percentage on principal amount       3.00%            
SVB Term Loan [Member] | Prepayment After First Anniversary of Effective Date and Prior To Second Anniversary of Effective Date [Member]                    
Prepayment premium percentage on principal amount       2.00%            
SVB Term Loan [Member] | Prepayment After Second Anniversary of the Effective Date and Prior to February 1, 2024 [Member]                    
Prepayment premium percentage on principal amount       1.00%            
SVB Term Loan [Member] | Prime Rate [Member]                    
Variable interest rate       1.00%            
SVB Term Loan [Member] | Prime Rate [Member] | Third Amendment [Member]                    
Variable interest rate   1.00%                
SVB Term Loan [Member] | Adjusted Prime Rate [Member]                    
Variable interest rate       3.00%